-

Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027 at a 5.3% CAGR - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Transdermal Scopolamine: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027

In the changed post COVID-19 business landscape, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.

The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR

The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Select Competitors (Total 41 Featured) -

  • Alchem International
  • Alkaloids of Australia
  • ALZA Corporation
  • Baxter International Inc.
  • Caleb Pharmaceuticals Inc
  • Centroflora-Cms
  • Fine Chemicals Corporation
  • GlaxoSmithKline Plc
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Phytex Australia

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Transdermal Scopolamine - Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

Companies Mentioned

  • Alchem International
  • Alkaloids of Australia
  • ALZA Corporation
  • Baxter International Inc.
  • Caleb Pharmaceuticals Inc
  • Centroflora-Cms
  • Fine Chemicals Corporation
  • GlaxoSmithKline Plc
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Phytex Australia

For more information about this report visit https://www.researchandmarkets.com/r/mjl3iv

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Industry:

Research and Markets

Release Versions
English

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Protein Engineering for Pharmaceutical Biotechnology Training Course: Understand How to Advance Therapeutic Development and Industrial Applications (Jan 21st - Jan 22nd, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Protein Engineering for Pharmaceutical Biotechnology Training Course (Jan 21st - Jan 22nd, 2026)" training has been added to ResearchAndMarkets.com's offering. Enhance your knowledge in protein engineering to understand how to advance therapeutic development and industrial applications. Protein-based therapeutics have significantly advanced and created new paradigms in disease treatment. Half of the top ten selling drugs in 2023 were protein-based therapeutics. Pro...

Development of Combination Products: 2 Day Critical Interactions Training Course (Feb 9th - Feb 10th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Development of Combination Products: Critical Interactions Training Course (Feb 9th - Feb 10th, 2026)" training has been added to ResearchAndMarkets.com's offering. The programme will cover the regulatory strategy to adopt and the relevant aspects of GMP and quality processes, including the data expectations for the CTD. It will also review the key relationships between quality, regulatory, R&D and production. Delegates will find this a comprehensive overview o...

Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course (Feb 11th - Feb 12th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course (Feb 11th - Feb 12th, 2026)" training has been added to ResearchAndMarkets.com's offering. This two-day workshop has been designed specifically for product developers who want to incorporate human factors testing into their product development or need to provide the regulators with specific usability data for their device to comply with the MDR. The format for the d...
Back to Newsroom